In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IsoRay moves Proxcelan plant to WA:

This article was originally published in Clinica

Executive Summary

Manufacturer of Proxcelan brachytherapy seeds IsoRay Medical is set to move production to a new facility in Richland, Washington. The new plant, which will house the company's radioactive and non-radioactive facilities, brings IsoRay's operations to a single location. Production of the company's primary product will be doubled and the company will undergo the development of isotopes for new cancer treatments. Proxcelan is the brand name for cesium-131 seeds designed to treat prostate cancer via low dose radiation. Although the technology has solely been used to treat prostate cancer, it received FDA clearance for the treatment of all malignancies in March 2003.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts